HGH Fragment 176-191

The HGH Fragment 176-191 is evolved from the Human Growth Hormone (HGH) computed as the last segments, 177 to 191 of amino acids. It is the lipolytic fragment portion of HGH, “known as AOD-9604 or simply the fat-reducing moiety,” that comprises this synthetic sequence. This fragment has proved its potential as a weight loss facilitator in the animal models of obesity. While it has a positive safety profile established through multiple clinical trials, it is to be noted that Fragment 176-191 remains a research chemical and has not yet been endorsed for therapeutic application.

HGH Fragment 176-191 is best known among peptides for sale for its fat mass reduction capacity. This peptide is highly significant beyond childhood development by causing a change in the way that our body absorbs fats and carbohydrates. It not only inhibits the work of LPL in fat tissues but also stimulates lipolysis in adipose tissue and brings a significant decrease in total body fat mass with an influence on the distribution of the residual fat. Due to its efficacy in decreasing fat but without affecting carbohydrate metabolism and IGF-1, the peptide is a good anti-obesity medicine. Evidence from work conducted on rodents indicates that Fragment 176-191 can lower blood sugar and increase insulin levels which may indicate its utility in diabetes type-2 and prediabetes.